Search details
1.
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Breast Cancer Res
; 26(1): 20, 2024 01 31.
Article
in English
| MEDLINE | ID: mdl-38297352
2.
Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
Pharmacogenet Genomics
; 34(4): 126-129, 2024 Jun 01.
Article
in English
| MEDLINE | ID: mdl-38359166
3.
Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer.
Breast Cancer Res Treat
; 204(3): 539-546, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38198070
4.
Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
Lancet
; 400(10364): 1704-1711, 2022 Nov 12.
Article
in English
| MEDLINE | ID: mdl-36366886
5.
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Breast Cancer Res Treat
; 202(1): 191-201, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37589839
6.
Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer.
Breast Cancer Res Treat
; 196(3): 535-547, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36197536
7.
The Impact of Radiotherapy Delay in Breast Conservation Patients Not Receiving Chemotherapy and the Rationale for Dichotomizing the Radiation Oncology Time-Dependent Standard into Two Quality Measures.
Ann Surg Oncol
; 29(1): 469-481, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-34324114
8.
Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations.
J Natl Compr Canc Netw
; 20(7): 738-744, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35830893
9.
Late effects in a high-risk population of breast cancer survivors.
Support Care Cancer
; 30(2): 1749-1757, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34586509
10.
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
Support Care Cancer
; 30(10): 8059-8067, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35776183
11.
A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing.
Qual Life Res
; 31(8): 2341-2355, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35133567
12.
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.
Pharmacogenet Genomics
; 31(5): 116-123, 2021 07 01.
Article
in English
| MEDLINE | ID: mdl-34096894
13.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Article
in English
| MEDLINE | ID: mdl-29863451
14.
Development of new brain metastases in triple negative breast cancer.
J Neurooncol
; 152(2): 333-338, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33512631
15.
Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
Breast Cancer Res Treat
; 184(3): 965-975, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-32914353
16.
The effect of 1-day multidisciplinary clinic on breast cancer treatment.
Breast Cancer Res Treat
; 182(3): 623-629, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32507956
17.
Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period.
Breast Cancer Res Treat
; 180(3): 695-706, 2020 Apr.
Article
in English
| MEDLINE | ID: mdl-32162192
18.
High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.
Breast Cancer Res Treat
; 179(1): 25-35, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31531802
19.
Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study.
Carcinogenesis
; 40(7): 903-913, 2019 07 20.
Article
in English
| MEDLINE | ID: mdl-31046118
20.
Survivorship care visits in a high-risk population of breast cancer survivors.
Breast Cancer Res Treat
; 173(3): 701-708, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-30406364